Drug Trial Radar · NCT07712939
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Mar 31, 2028
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Candid TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
Conditions
- Healthy Participants Study
- Rheumatoid Arthritis
- Sjogren's Syndrome
Interventions
CND319Biological
CND319
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence proportion and severity of treatment-emergent adverse events through end of studyTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes to body temperatureTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes to heart rateTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes to respiratory rateTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes to blood pressureTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes to pulse oximetryTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes from baseline in ECG parameters through end of study: PR intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes from baseline in ECG parameters through end of study: QRS intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes from baseline in ECG parameters through end of study: QT intervalTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
- Changes from baseline in safety laboratory assessments through end of studyTime frame: Baseline through Week 12 (SAD) or Week 24 (MAD/Part 2)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Candid Clinical Site
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.